revenue generated by each of these top-selling products in their first five full years on the market
Smoking cessation after successful treatment of smallcell lung cancer is associated with fewer smokingrelated second primary cancers
There are several phase 3 trials evaluating GLP-1s for indications, such as metabolic dysfunction-associated steatohepatitis (MASH), prediabetes, Alzheimer's disease, diabetic retinopathy, and osteoarthritis of the knee (in patients with obesity)
The semaglutide group had a 0.33 percentage point reduction in HbA1c ( P = .034), a 0.37 mmol/L decrease in total cholesterol ( P = .04) and a 0.29 mmol/L decline in LDL cholesterol ( P = .05) from baseline to 1 year
"I saw a visible difference in my skin tone after 4 weeks
Mounjaro metabolic benefits Tirzepatide consistently demonstrates improvements across multiple metabolic markers: Blood sugar control: HbA1c reductions of 1.87% to 2.07% in type 2 diabetes trials Blood pressure: Modest systolic blood pressure reductions of 4-7 mmHg Lipids: Improvements in triglycerides and cholesterol profiles Waist circumference: Significant reductions correlating with visceral fat loss Inflammatory markers: Reductions in high-sensitivity C-reactive protein These benefits make tirzepatide more than just a weight loss drug